Esranur Aydın: Therapeutic vulnerabilities and pan-cancer landscape of BRAF mutations in epithelial solid tumors

Esranur Aydın shared on LinkedIn about recent paper by her as co-author, titled “Therapeutic vulnerabilities and pan-cancer landscape of BRAF class III mutations in epithelial solid tumors” published on BJC Reports.

Authors: Eylül Özgü, Benjamin G. Kaplan, Smruthy Sivakumar, Ethan S. Sokol, Esranur Aydın, Ünal Metin Tokat, Ashkan Adibi, Ebru Gül Karakoç, Jiancheng Hu, Razelle Kurzrock, Mutlu Demiray

“To improve patient outcomes, we must understand different classes of BRAF alterations:

Let me share the release of our latest paper in BJC Reports, “Therapeutic vulnerabilities and pan-cancer landscape of BRAF class III mutations in epithelial solid tumors” in partnership with Foundation Medicine!

This research marks a major breakthrough, analyzing the genomic profiles of over 376,000 patients—a massive scale rarely achieved in cancer studies!

Our deep dive into BRAF class 3 mutations (BRAF v3) uncovered transformative insights. These mutations not only define a distinct tumor subset with unique genomic traits but also reveal that anti-EGFR therapies could offer significant treatment benefits. This might open a new chapter in the fight against rare and hard-to-treat cancers!

Key Highlights:

– BRAF v3 mutations make tumors potentially more responsive to anti-EGFR therapies offering new treatment options.
– Tumors with BRAF v3 show fewer resistance-related alterations, boosting the chances of successful targeted therapies.
– Screening rare tumors for BRAF class III mutations could unlock life-saving treatments for patients with limited options.

We’re genuinely excited about the impact this research could have, and maybe even a little proud of what we’ve achieved together! ”

Esranur Aydın is a Clinical Cancer Molecular Biologist at Medicana Sağlık Grubu, Istanbul. She focuses on precision oncology, utilizing genomic profiling and multidisciplinary tumor boards to develop tailored treatments, ensuring each patient receives the most effective therapy based on their cancer’s molecular profile.